Latest Ratios: P/E Ratio 47.4x · EV/EBITDA 25.7x · ROE 12.5%. (2017–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $2.4B | $2.3B | $1.6B | $3.7B | $3.1B | $5.1B | $4.2B | $2.3B | — | — |
| Enterprise Value | $2.3B | $2.2B | $1.5B | $3.7B | $3.0B | $5.0B | $4.1B | $2.2B | — | — |
| P/E Ratio → | 47.35 | 39.51 | 30.26 | 59.97 | 103.83 | 76.29 | 90.19 | — | — | — |
| P/S Ratio | 1.87 | 1.78 | 1.41 | 3.44 | 3.96 | 10.09 | 12.18 | 9.99 | — | — |
| P/B Ratio | 5.34 | 4.45 | 3.90 | 6.76 | 8.26 | 20.07 | 25.15 | 20.08 | — | — |
| P/FCF | 12.57 | 11.98 | 9.48 | 20.21 | 40.36 | 211.35 | 119.40 | — | — | — |
| P/OCF | 11.47 | 10.93 | 9.19 | 19.82 | 38.73 | 194.07 | 115.98 | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.71 | 1.29 | 3.37 | 3.81 | 9.93 | 12.00 | 9.64 | — | — |
| EV / EBITDA | 25.74 | 24.49 | 21.29 | 56.85 | 120.33 | 147.74 | 403.57 | 187.44 | — | — |
| EV / EBIT | 27.24 | 23.15 | 22.29 | 58.94 | 128.58 | 153.69 | 495.71 | 228.76 | — | — |
| EV / FCF | — | 11.52 | 8.66 | 19.79 | 38.90 | 207.89 | 117.68 | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 23.6% | 23.6% | 21.7% | 21.9% | 21.3% | 22.4% | 20.3% | 19.8% | 18.4% | 15.2% |
| Operating Margin | 6.6% | 6.6% | 5.8% | 5.7% | 3.0% | 6.5% | 2.4% | 4.2% | -3.3% | -22.7% |
| Net Profit Margin | 4.5% | 4.5% | 4.7% | 5.7% | 3.9% | 13.1% | 13.5% | -3.7% | 0.6% | -25.6% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 12.5% | 12.5% | 11.1% | 13.3% | 9.7% | 31.4% | 33.0% | -13.7% | 6.1% | -116.5% |
| ROA | 8.7% | 8.7% | 8.0% | 9.5% | 6.7% | 21.5% | 23.0% | -8.9% | 1.7% | -35.6% |
| ROIC | 18.1% | 18.1% | 13.4% | 12.6% | 8.1% | 17.6% | 8.9% | 32.2% | -23.1% | -73.8% |
| ROCE | 17.4% | 17.4% | 13.4% | 13.0% | 7.3% | 14.9% | 5.7% | 15.4% | -24.4% | -64.0% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.05 | 0.05 | 0.05 | 0.04 | 0.02 | 0.03 | 0.06 | — | 0.02 | 0.49 |
| Debt / EBITDA | 0.27 | 0.27 | 0.27 | 0.30 | 0.31 | 0.26 | 0.93 | — | — | — |
| Net Debt / Equity | — | -0.17 | -0.34 | -0.14 | -0.30 | -0.33 | -0.36 | -0.70 | 0.01 | 0.05 |
| Net Debt / EBITDA | -0.98 | -0.98 | -2.03 | -1.21 | -4.51 | -2.46 | -5.93 | -6.81 | — | — |
| Debt / FCF | — | -0.46 | -0.82 | -0.42 | -1.46 | -3.46 | -1.73 | — | 0.07 | — |
| Interest Coverage | — | — | — | — | — | — | — | 166.84 | -6.95 | -14.87 |
Net cash position: cash ($112M) exceeds total debt ($24M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.73 | 2.73 | 2.80 | 3.44 | 2.72 | 2.62 | 2.45 | 3.66 | 0.81 | 0.94 |
| Quick Ratio | 2.73 | 2.73 | 2.80 | 3.44 | 2.72 | 2.62 | 2.45 | 3.66 | 0.81 | 0.94 |
| Cash Ratio | 1.53 | 1.53 | 1.35 | 2.00 | 1.19 | 1.21 | 1.41 | 2.22 | 0.00 | 0.26 |
| Asset Turnover | — | 1.74 | 1.92 | 1.44 | 1.45 | 1.40 | 1.36 | 1.53 | 2.55 | 1.39 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 62.39 | 73.59 | 81.10 | 111.35 | 98.10 | 80.08 | 74.78 | 80.77 | 85.44 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 2.1% | 2.5% | 3.3% | 1.7% | 1.0% | 1.3% | 1.1% | — | — | — |
| FCF Yield | 8.0% | 8.3% | 10.5% | 4.9% | 2.5% | 0.5% | 0.8% | — | — | — |
| Buyback Yield | 3.4% | 3.6% | 18.2% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 3.4% | 3.6% | 18.2% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $89M | $95M | $101M | $100M | $100M | $99M | $84M | $82M | $6M |
Enterprise client concentration risk
Based on current market data, PGNY trades at a forward P/E of 22.29, which appears elevated given the recent deceleration in revenue growth and the loss of key enterprise clients as documented in the company's most recent quarterly financial disclosures and management commentary.
The current valuation multiple suggests that investors are still pricing in a high-growth trajectory that may no longer align with the company's maturing client base. When compared to peers like GoodRx, the premium appears difficult to justify without a clear path to re-accelerating member life additions.
As reported in financial statements, PGNY's ROIC has fluctuated between 2.4% and 6.9% over the last ten quarters, indicating that the company is struggling to consistently compound returns on its invested capital despite its asset-light business model and lack of significant physical infrastructure requirements.
The volatility in ROIC suggests that the company's profitability is highly sensitive to the timing of clinical utilization and the associated medical cost ratios. Investors should monitor whether management can improve these returns as the business scales or if structural margin caps will continue to suppress capital efficiency.
According to quarterly data, the company's DSO has remained elevated, averaging between 66 and 92 days over the past ten quarters, which highlights the inherent friction in collecting payments from large, self-insured enterprise clients within the complex healthcare benefits administration ecosystem.
This extended collection cycle suggests that Progyny acts as a significant financing intermediary for its clients, which may pressure cash flow during periods of rapid growth. The lack of a clear trend in the cash conversion cycle warrants further investigation into the company's underlying billing and collection efficiency.
Institutional analysts frequently misapply the Price-to-Sales ratio to Progyny, as this metric fails to account for the significant pass-through nature of medical and pharmacy claims costs that inflate the top-line revenue figure without contributing to the company's actual economic value or net profitability.
A more appropriate metric for this business model would be an adjusted EV/Gross Profit or EV/EBITDA ratio, which better captures the company's role as a benefit manager rather than a traditional service provider. Relying on P/S obscures the true margin profile and the impact of fluctuating medical cost ratios.
Includes 30+ ratios · 9 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying PGNY stock.
Progyny, Inc.'s current P/E ratio is 47.4x. The historical average is 66.7x. This places it at the 33th percentile of its historical range.
Progyny, Inc.'s current EV/EBITDA is 25.7x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 34.2x.
Progyny, Inc.'s return on equity (ROE) is 12.5%. The historical average is -1.4%.
Based on historical data, Progyny, Inc. is trading at a P/E of 47.4x. This is at the 33th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Progyny, Inc. has 23.6% gross margin and 6.6% operating margin.
Progyny, Inc.'s Debt/EBITDA ratio is 0.3x, indicating low leverage. A ratio below 2x is generally considered financially healthy.